We are live on ! Find out more
CRXTW

Clarus Therapeutics Holdings, Inc. Warrants
CRXTW

Delisted

CRXTW was delisted on the 30th of August, 2022.

Back to rankings

19 hedge funds and large institutions have $966K invested in Clarus Therapeutics Holdings, Inc. Warrants in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% less funds holding

Funds holding: 22 → 19 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

69% less capital invested

Capital invested by funds: $3.13M → $966K (-$2.17M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 9

Holders
19
Holders Change
-3
Holders Change %
-13.64%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
9
Closed
5
Calls
$608K
Puts
–
Net Calls
+$608K
Net Calls Change
+$55K

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$371K
2
PAMP
Polar Asset Management Partners
Ontario, Canada
-$132K
3
CH
CVI Holdings
Delaware
-$107K
4
AC
Aristeia Capital
Connecticut
-$94.2K
5
BFM
Boothbay Fund Management
New York
-$68K

CRXTW Hedge Fund Activity: Q4 2021 in Review

19 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) for Q4 2021, worth a combined $966K — down 69% from $3.13M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CRXTW and 2 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 0 added.

The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $371K sold.

  • 19 institutional investors held Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) as of Q4 2021, down from 22 in Q3 2021.
  • Funds reported $966K of Clarus Therapeutics Holdings, Inc. Warrants stock for Q4 2021, down 69% quarter-over-quarter.
  • 2 funds opened new Clarus Therapeutics Holdings, Inc. Warrants positions in Q4 2021 and 5 closed out, a net change of -3 holders.
  • The largest Clarus Therapeutics Holdings, Inc. Warrants seller in Q4 2021 was Radcliffe Capital Management, an estimated $371K sold.

Based on aggregated 13F filings for Q4 2021.